

# An Overview of GEOVAC: A Software Application to Monitor Immunization Performance in Georgia

---

*Second version, January 2004*

---

Developed by:

---

**Anton Luchitsky, MD**  
Program for Appropriate  
Technology in Health

**Galina Romanyuk, MD**  
Program for Appropriate  
Technology in Health

*For:*

Partners for Health Reform*plus*

*In cooperation with:*

Ministry of Labor, Health and  
Social Affairs of Georgia

National Center for Disease  
Control

Curatio International Foundation



Ministry of Labor, Health and Social Affairs  
National Center for Disease Control and  
Medical Statistics



Curatio International  
Foundation



Partners for Health Reform*plus*



Abt Associates Inc. ■ 4800 Montgomery Lane, Suite 600  
Bethesda, Maryland 20814 ■ Tel: 301/913-0500 ■ Fax: 301/652-3916

*In collaboration with:*

Development Associates, Inc. ■ Emory University Rollins School of Public  
Health ■ Philoxenia International Travel, Inc. ■ Program for Appropriate  
Technology in Health ■ Social Sectors Development Strategies, Inc. ■  
Training Resource Group ■ Tulane University School of Public  
Health and Tropical Medicine ■ University Research Co., LLC.



*Funded by:*  
U.S. Agency for International Development

*Order No. TE 035*





## **Mission**

*Partners for Health Reformplus is USAID's flagship project for health policy and health system strengthening in developing and transitional countries. The five-year project (2000-2005) builds on the predecessor Partnerships for Health Reform Project, continuing PHR's focus on health policy, financing, and organization, with new emphasis on community participation, infectious disease surveillance, and information systems that support the management and delivery of appropriate health services. PHRplus will focus on the following results:*

- ▲ *Implementation of appropriate health system reform.*
- ▲ *Generation of new financing for health care, as well as more effective use of existing funds.*
- ▲ *Design and implementation of health information systems for disease surveillance.*
- ▲ *Delivery of quality services by health workers.*
- ▲ *Availability and appropriate use of health commodities.*

This document was produced by PHRplus with funding from the US Agency for International Development (USAID) under Project No. 936-5974.13, Contract No. HRN-C-00-95-00024 and is in the public domain. The ideas and opinions on this document are the authors and do not necessarily reflect those of USAID or its employees. Interested parties may use the report in part or whole, providing they maintain the integrity of the report and do not misrepresent its findings or present the work as their own. This and other HFS, PHR, and PHRplus documents can be viewed and downloaded on the project website, [www.PHRplus.org](http://www.PHRplus.org).

## **Second version, January 2004**

### **Recommended Citation**

Anton Luchitsky and Galina Romanyuk. January 2004. *An Overview of GEOVAC: A Software Application to Monitor Immunization Performance in Georgia*. Second Version. Bethesda, MD: The Partners for Health Reformplus Project, Abt Associates Inc.

For additional copies of this report, contact the PHRplus Resource Center at [PHR-InfoCenter@abtassoc.com](mailto:PHR-InfoCenter@abtassoc.com) or visit our website at [www.PHRplus.org](http://www.PHRplus.org).

**Contract/Project No.:** HRN-C-00-00-00019-00

**Submitted to:** USAID/Caucasus

and: Karen Cavanaugh, CTO  
Health Systems Division  
Office of Health, Infectious Disease and Nutrition  
Center for Population, Health and Nutrition  
Bureau for Global Programs, Field Support and Research  
United States Agency for International Development



# Abstract

The GEOVAC software application is a tool designed to help personnel of regional level centers of public health and the National Center for Disease Control in Georgia process a large flow of immunization-related data in much less time than the previous (manual) system. It allows them to quickly identify issues and deficiencies regarding immunization coverage, and use and distribution of vaccines, and to assess adequacy of supplies as well as major barriers (medical contraindications, parental refusals, etc.) to the functioning of the immunization system. In doing so, GEOVAC gives health workers more time to focus on the utilization of MIS data for management and disease outbreak response purposes. This second version of the application has gone through numerous revisions and suggestions based on testing in the pilot region. It is now being used nationwide.

The current document illustrates GEOVAC functions, relating them to the features of the upgraded Georgian immunization information system and demonstrating what it can offer immunization managers in the decision making process. It is designed primarily for policymakers in countries planning to strengthen their immunization and/or surveillance systems, donor organizations that can support such reforms and agencies working in these technical areas. It can also help policymakers and health workers in Georgia to plan and implement similar reforms in other sectors of the health care system.

---



# Table of Contents

Acronyms .....	ix
Contributors .....	xi
Acknowledgments.....	xiii
1. Introduction .....	1
2. System Requirements.....	3
3. Data Entry .....	5
4. GEOVAC Output.....	7
4.1 Monthly Summary Report on Immunization Practice .....	7
4.2 Tables and Graphs on Immunization Coverage .....	9
4.3 Tables and Graphs on Contraindications and Refusals.....	13
4.4 Tables and Graphs on Vaccine Flow and Use.....	15
5. In Conclusion .....	19
Annex: Sample District Level Immunization.....	21



# Acronyms

<b>BCG</b>	Bacillus, Calmette and Guerin Vaccine
<b>CPH</b>	Center for Public Health
<b>CIF</b>	Curatio International Foundation
<b>CMSI</b>	Center for Medical Statistics and Information
<b>DT</b>	Diphtheria and Tetanus Toxoid combination
<b>DPT</b>	Diphtheria, Pertussis and Tetanus vaccine
<b>MIS</b>	Management Information System
<b>MMR</b>	Measles, Mumps and Rubella vaccine
<b>MoLHSA</b>	Ministry of Labor, Health and Social Affairs
<b>NCDC</b>	National Center for Disease Control
<b>PC</b>	Personal Computer
<b>PHR<i>plus</i></b>	Partners for Health Reform <i>plus</i> Project
<b>Td</b>	Tetanus and Diphtheria Toxoid
<b>USAID</b>	United States Agency for International Development



# Contributors

The second edition of the software application has been developed based on the numerous comments, ideas, and suggestions of the Ministry of Labor, Health and Social Affairs (MoLHSA) Expanded Working Group headed by Dr. P. Imnadze, Director of the National Center for Disease Control (NCDC), and Curatio International Foundation.

The working group also included the following:

<i>Ramaz Urushadze</i>	Head of the Public Health Department, MoLHSA
<i>Paata Imnadze</i>	Director, NCDC
<i>Levan Baidoshvili</i>	Immunization Program Coordinator, NCDC
<i>Manana Tsintsadze</i>	Head, Center for Medical Statistics and Information (CMSI)
<i>Marina Shakh-Nazarova</i>	Head, Data Analysis & Presentation Division, CMSI
<i>Tamar Dolakidze</i>	Head, Logistics and Immunization Department, NCDC
<i>Lia Djabidze</i>	Logistics and Immunization Department, NCDC
<i>Gia Chirakadze</i>	Deputy Head, Public Health Department, MoLHSA
<i>Ketevan Galdavdze</i>	Chief Specialist of Surveillance Division, Public Health Department, MoLHSA
<i>Neli Khizanishvili</i>	Director, Kakheti Regional Public Health Center
<i>Lili Zautashvili</i>	Deputy Director, Kakheti Regional Public Health Center
<i>Merab Sepashvili</i>	Director, Kvareli Rayon Public Health Center
<i>Nunu Nozadze</i>	Director, Lagodekhi Rayon Public Health Center
<i>Lela Otarashvili</i>	Director, Sagarejo Rayon Public Health Center
<i>Lamara Jangirashvili</i>	Deputy Director, Telavi Rayon Public Health Center
<i>Niko Aivazashvili</i>	Chief Doctor, Polyclinics-Ambulatory Unit, Telavi
<i>Natela Tsikaradze</i>	Doctor/Statistician, Polyclinics-Ambulatory Unit, Telavi
<i>Ketevan Gelashvili</i>	Deputy Director, Telavi Rayon Public Health Rayon Center
<i>Ketino Rostomashvili</i>	Doctor/Statistician, Children's Polyclinic in Telavi
<i>Tamriko Sisauri</i>	Statistician, Telavi Rayon Public Health Center



# Acknowledgments

The MoLHSA of Georgia and the authors of this document are grateful to the *U.S. Agency for International Development (USAID/Caucasus)* for the opportunity to realize plans on elaboration and introduction of the software application for the new immunization information system in Georgia as well as to *the USAID Global Bureau in Washington* for the opportunity to develop and produce this document.

The authors would like to thank Paata Imnadze and Ramaz Urushadze at the *Ministry of Labor, Health and Social Affairs in Tbilisi* for their support in the design and implementation of the immunization information system; Mamuka Djibuti, Ivdity Chikovani, George Gotsadze, and Natia Rukhadze of the *Curatio International Foundation* for their contribution to the design and the development of both the information system and the software application; and Lynne Miller Franco of the *Partners for Health Reformplus Project* for the technical review of this publication.

The production of this software application was funded by USAID under the prime contract No. HRN-C-00-00-00019-00 and subcontract No. 02-011-HPSS-7544.

The data shown in forms and graphs in this publication are not associated with real institutions and are used for illustrative purposes only.



# 1. Introduction

The software application GEOVAC (refers to Georgia Vaccination) is a supplement to the immunization management information system (MIS) in Georgia that helps health workers at the National Center for Disease Control (NCDC) and regional centers of public health to do the following:

- ▲ Process a large flow of immunization program data in a timely manner. The application contains nearly 15,000 formulas to provide an insight into various aspects of the operation of the country's immunization program.
- ▲ Quickly draw the immunization manager's attention to regions or districts with suboptimal performance and specify the nature of the problem.
- ▲ Present information in a suitable form for decision making and for feedback to health workers at lower level.
- ▲ Store the data electronically for future reference.

A two-year test of GEOVAC in Georgia has proved this tool to be invaluable, as it allows a contemporary analysis of how the immunization program functions. Apart from the fact that it would be extremely difficult for such a comprehensive analysis to be done manually within a reasonable timeframe (approximately 1,000 calculations are required monthly), health workers at the central and regional levels in Georgia no longer believe that a manual exercise of this sort represents the best use of their professional time, because information technology has become widely available at these levels.

GEOVAC also fulfills Georgia's need for standardized immunization data processing tool for use throughout the national health system; thus, it obviates the development of non-standardized IT-based tools that some individual institutions had begun to create.

This document gives an overview of GEOVAC: It describes systems requirements, data entry procedures, and outputs produced on a routine basis. It also relates GEOVAC functions to the features of the upgraded Georgian immunization information system and demonstrates what it can offer immunization managers in the decision-making process.

As such, the document is designed primarily for policymakers in countries planning to strengthen their immunization and/or surveillance systems, donor organizations that can support such reforms, and agencies working in these technical areas. The document can also help policymakers and health workers in Georgia to plan and implement similar reforms in other sectors of the health care system.



## 2. System Requirements

The GEOVAC system requirements are minimal. Users must have a Pentium-class computer with at least 32 MB RAM and 30 MB free disk space. Any computer manufactured in 1998 or later will meet these requirements.

Users also must have Excel (Excel-97 or a newer version) installed on their computers, because GEOVAC is based on the Excel platform and contains Visual Basic for Applications program code.

Excel was chosen because it meets the following criteria:

- ▲ It is part of the Microsoft Office package, widely available and used in Georgia.
- ▲ It is simple, reliable, and virus-resistant.
- ▲ It does not require support of skilled programmers.

GEOVAC maintenance skills have been successfully transferred to the immunization program personnel in Georgia and, in fact, the Georgian language version of the application is currently in use in the country.

- ▲ It can be modified and new modules can be easily added.
- ▲ The database is easy to store and archive.
- ▲ The graphics presentation function built into Excel helps utilize the data in the decision-making process.



## 3. Data Entry

Data from district-level immunization reports (a sample report is in the annex to this manual) are entered on a monthly basis into the database at the regional centers of public health by an assistant epidemiologist or a PC operator. Data entry usually takes no more than two hours per region per month.

During this process an operator can verify data accuracy and protect the database from accidental mistakes using standard Excel features such as:

- ▲ Data validation
- ▲ Automatic verification of totals
- ▲ Conditional formatting of data entered

These features are fully used in the GEOVAC application.

After the data entry, regional immunization managers can immediately begin analyzing the dataset. A summary regional report is generated instantaneously and can be e-mailed to the NCDC.



## 4. GEOVAC Output

The GEOVAC standard automatic output files include the following reports:

- ▲ Monthly summary report on immunization practice
- ▲ Tables and graphs on immunization coverage
- ▲ Tables and graphs on major barriers to timely immunization, such as medical contraindications or parental refusals
- ▲ Tables and graphs on the timeliness of primary vaccination
- ▲ Tables and graphs on the use of vaccines

The information in all GEOVAC output (report or analytical) files is derived from the database and is protected from manual changes to preclude tampering with output numbers.

The standard Excel conditional formatting function helps quickly identify issues requiring prompt attention of the manager.

The following sections describe the GEOVAC output in more detail and illustrate many of the GEOVAC functions for both regional and national levels.

---

### 4.1 Monthly Summary Report on Immunization Practice

The monthly summary report (produced both at regional and national level) is generated from the entry of individual rayon summary reports and contains information about the number and types of all immunizations given, use of vaccines, medical contraindications to DPT 1-3 (this vaccine has been chosen as a marker), and timeliness of primary DPT series.

REPORT on CONDUCTED PREVENTIVE VACCINATIONS												
Georgia			December			2003						
Immunizations Given						Use of Vaccine in Doses						
Vaccine	Age at vaccination	Target	No. vaccinated this month	Cumulative	%	Total immunizations given this month	Balance with Regional CPH at the beginning of the period (doses)	Received (doses)	ISSUED / destroyed / written off (doses)	Balance at the end of the period (doses)	Balance at Regional CPH at the end of the period (doses)	TOTAL AMOUNT OF VACCINE UTILIZED (doses)
1	2	3	4	5	6	7	8	9	10	11=8+9-10	12 mon col.10 (2)	13 mon col.10 (2)
BCG-v	0-5 days	48,262	2832	35462	80.7%	3621	11640	8060	10920	8780	8870	8884
	5 days-11mo29d		726	3473								
	More than 1 year	2,048	15	509	24.9%							
BCC-2	6 years -	52,541	48	9147	17.4%							
DPT-1	2 months-11mo29d		3221	38358		13708	27250	10560	16966	20844	17401	17155
Diphtheria-Tetanus- Pertuisis-1	More than 1 year		392	401								
DPT-2	3 months-11mo29d		2872	35447								
Diphtheria-Tetanus-Pertuisis-2	More than 1 year		421	5632								
DPT-3	4 months-11mo29d	44,490	2989	33604	75.3%	8988	15420	3820	11030	8210	12430	12423
Diphtheria-Tetanus-Pertuisis-3	More than 1 year	13,206	545	7147	54.3%							
DPT-4	18 - 24 months	43,664	2591	27866	63.8%							
Diphtheria-Tetanus-Pertuisis-4	More than 24 months		677	10874								
DT-1	under 1 year		52	369		8988	15420	3820	11030	8210	12430	12423
Diphtheria-Tetanus- 1	More than 1 year		209	827								
DT-2	under 1 year		37	229								
Diphtheria-Tetanus- 2	More than 1 year		164	573								
DT-3	under 1 year		42	208								
Diphtheria-Tetanus- 3	More than 1 year	6,602	94	460	7.0%							
DT-4	18 months -	5,167	285	1423	27.5%							
DT	5 years- 5 yllmo29d	52,501	7267	24155	46.0%							
Diphtheria-Tetanus	More than 6 years		838	4231								
OPV-1	2 months-11mo29d		3090	37927		20730	23360	13450	30230	6580	20894	26006
Polio myelitis - 1	More than 1 year		537	5894								
OPV-2	3 months-11mo29d		2822	35165								
Polio myelitis - 2	More than 1 year		524	6020								
OPV-3	4 months-11mo29d	44,490	2972	33300	74.8%							
Polio myelitis - 3	More than 1 year	19,845	592	7485	37.7%							
OPV-4	18 - 24 months	44,057	2599	28305	64.2%							
Polio myelitis - 4	More than 24 months		855	10843								
OPV-5	5 years- 5 yllmo29d	52,478	6058	28470	54.3%							
Polio myelitis - 5	More than 6 years		654	5364								
Other OPVs		4,750	27	4799	484.0%							
VHB-1	0 - 24 hours	44,144	2877	9597	21.7%	12198	28500	8142	16416	20226	15290	14406
Viral Hepatitis B-1	25 hours - 11mo29d		2574	30495								
	More than 1 year		282	5054								
VHB-2	2 months - 11mo29d		2897	29274								
Viral Hepatitis B-2	More than 1 year		411	5940								
VHB-3	3 months - 11mo29d	44,490	2163	21505	48.3%							
Viral Hepatitis B-3	More than 1 year	14,544	881	12202	83.9%							
Other VHB-1			26	459								
Other VHB-2			41	321								
Other VHB-3		0	46	606	#DIV/0!							
Measles 1	12 - 24 month	44,087	2787	36135	82.3%	6392	17622	7670	12840	12452	11406	10041
Measles 2	More than 24 months	15,186	486	8614	57.0%							
Measles - 2	5 years- 5 yllmo29d	52,535	2785	29984	57.1%							
Other Measles	More than 6 years		334	4995								
Mumps	12 - 24 month	44,087	4160	33915	77.3%	5754	23268	4560	11970	15858	8526	6900
Other Mumps	More than 24 months	249,415	1574	19075	7.7%							
		0	20	174	#DIV/0!							
Rubella	12 - 24 month	44,087	149	1188	3.1%	274	0	0	0	0	210	321
	More than 24 months	0	125	1013	#DIV/0!							
MMR	12 - 24 months		57	158		80	0	0	0	0	26	80
	More than 24 months		10	41								
	5 years- 5 yllmo29d		13	13								
MR	More than 6 years		0	3								
Td Tetanus - Diphtheria	12 - 24 months		0	7		0	0	0	0	0	0	0
	More than 24 months		0	0								
	5 years- 5 yllmo29d		0	0								
Td Other	More than 6 years		0	0								
Syringe Disposal Containers	14 years	68,801	5586	44632	64.9%	Total	21280	4000	9660	15620	12986	8333
			400	4217		Total	5986					
							517	0	86	431	530	189
TIMELINESS	No. of children born in July 2003 (3mo prior to the reported one)=>					2528						
	Of them - no. of children who finished primary immunization at 4mo29d =>					1176						
REFUSALS	CONTRAINDICATIONS TO DTP											
							Short-term	Long-term	Permanent			
DTP-1 (under 1y)	536		DTP-1 (under 1y)				855	430	75			
DTP-2 (under 1y)	129		DTP-2 (under 1y)				336	68	15			
DTP-3 (under 1y)	70		DTP-3 (under 1y)				248	43	6			
TOTAL REFUSALS	735		TOTAL contraindications (short+long+perm)				17.5%		2,076			

Number and types of immunization given, cumulative numbers, coverage rates.

Vaccine flow, usage and balances

Refusals

Timeliness of immunization

Contraindications

## 4.2 Tables and Graphs on Immunization Coverage

Achieving high immunization coverage rates (80-95 percent) of all target groups in all geographical areas is a key to keeping the vaccine-preventable disease epidemiological situation under control. GEOVAC makes monitoring of coverage rates and untimely immunizations an easy task for managers.

Monthly and cumulative data are presented in tables and dynamically built graphs for all antigens: BCG, polio (1-5), DTP (1-4), DT, Td, hepatitis B, and measles, mumps, rubella. The types of information that are automatically available for analysis include: immunization coverage rates broken down by region or district; “drop-out” rates for DPT, polio, hepatitis B vaccines; proportion of children immunized after established “deadlines”; proportion of children immunized with DT instead of DPT vaccine; proportion of children getting the first dose of the birth dose of the hepatitis B vaccine in compliance with the new regulations.


The following graphs illustrate some examples of how the application functions relate to the monitoring of selected immunization program indicators and how, using cross-analysis with other available data, managers can begin to understand what might be causing some of the performance problems they see.

### ▲ Immunization coverage

A review of the data in the GEOVAC immunization monitoring table can help managers identify both missed opportunities for vaccination and possible inventory issues.


Immunization coverage (%) monitoring sheet for Measles, Mumps, Rubella													Measles, Mumps, Rubella		Region ZZ		2003																	
Rayon/Town	Target	No. of measles-1 vaccinations given to children aged 12-24 mo											Total	%	Target	Measles-1 given to children over 24 mo											Total	%	Over 24mo as % of all Measles 1					
		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov				Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct				Nov	Dec			
District 1	465	43	50	31	25	42	27	34	0	0	0	0	0	252	54.2%	156	6	5	4	2	0	1	0	0	0	0	0	0	0	0	0	18	11.5%	6.7%
District 2	637	59	34	55	55	59	52	44	0	0	0	0	0	358	56.2%	210	1	2	2	2	3	8	2	0	0	0	0	0	0	0	0	20	9.5%	5.3%
District 3	247	31	18	22	17	13	8	24	0	0	0	0	0	133	53.8%	98	1	5	5	2	2	1	1	0	0	0	0	0	0	0	17	17.3%	11.3%	
District 4	766	35	78	62	63	63	54	53	0	0	0	0	0	408	53.3%	287	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
District 5	566	66	29	27	36	33	52	36	0	0	0	0	0	279	49.3%	99	14	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
District 6	631	67	44	51	58	37	39	55	0	0	0	0	0	351	55.6%	81	19	2	0	0	7	0	0	0	0	0	0	0	0	0	0	0	0	0
District 7	349	16	24	32	35	10	23	25	0	0	0	0	0	165	47.3%	333	11	1	6	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0
District 8	348	17	29	17	28	34	20	23	0	0	0	0	0	168	48.3%	8	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>TOTAL</b>	<b>4,000</b>	<b>334</b>	<b>306</b>	<b>297</b>	<b>317</b>	<b>291</b>	<b>276</b>	<b>294</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2,114</b>	<b>52.7%</b>	<b>1,272</b>	<b>52</b>	<b>28</b>	<b>17</b>	<b>29</b>	<b>49</b>	<b>25</b>	<b>22</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>222</b>	<b>17.5%</b>	<b>9.5%</b>	
Rayon/Town	Target	No. of mumps vaccinations given to children aged 12-24 mo											Total	%	Target	Mumps vaccinations given to children over 24 mo											Total	%	Over 24mo as % of all Mumps					
		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov				Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct				Nov	Dec			
District 1	465	3	88	28	53	49	31	8	0	0	0	0	0	260	55.9%	3,352	5	12	8	6	5	15	1	0	0	0	0	0	0	0	52	1.7%	16.7%	
District 2	637	3	3	3	3	3	3	3	3	3	3	3	3	219	34.4%	6,353	0	0	0	0	0	0	82	8	0	0	0	0	0	0	90	1.4%	29.1%	
District 3	247	31	18	22	23	13	18	28	0	0	0	0	0	147	59.5%	2,719	61	78	47	7	17	5	3	0	0	0	0	0	0	0	218	8.0%	59.7%	
District 4	766	35	78	62	63	63	49	53	0	0	0	0	0	403	52.6%	6,788	89	28	170	69	29	9	20	0	0	0	0	0	0	414	6.1%	50.7%		
District 5	566	82	30	17	57	4	30	36	0	0	0	0	0	276	48.8%	5,637	7	59	93	51	20	29	30	0	0	0	0	0	0	339	6.0%	55.1%		
District 6	631	67	44	51	33	9	7	12	0	0	0	0	0	205	32.2%	10,934	75	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
District 7	349	16	24	32	35	10	17	25	0	0	0	0	0	159	45.6%	2,026	78	107	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
District 8	348	17	29	17	43	25	20	26	0	0	0	0	0	177	50.9%	1,560	62	137	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>TOTAL</b>	<b>4,000</b>	<b>251</b>	<b>311</b>	<b>289</b>	<b>307</b>	<b>173</b>	<b>377</b>	<b>216</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1,844</b>	<b>46.8%</b>	<b>39,000</b>	<b>375</b>	<b>459</b>	<b>408</b>	<b>176</b>	<b>196</b>	<b>210</b>	<b>111</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1,935</b>	<b>5.0%</b>	<b>51.2%</b>	
Rayon/Town	Target	No. of rubella vaccinations given to children aged 12-24 mo											Total	%	Target	Rubella vaccinations given to children over 24 mo											Total	%	Over 24mo as % of all Rubella					
		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov				Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct				Nov	Dec			
District 1	465	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	#DIV/0!	
District 2	637	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	#DIV/0!	
District 3	247	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	#DIV/0!	
District 4	766	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	#DIV/0!	
District 5	566	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	#DIV/0!	
District 6	631	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	#DIV/0!	
District 7	349	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	#DIV/0!	
District 8	348	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	#DIV/0!	
<b>TOTAL</b>	<b>4,000</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0.0%</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>#DIV/0!</b>		

These data can also be shown graphically, allowing for easy comparison between districts. Cross-analysis of the data from various tables allows immunization managers to identify specific reasons for underperformance of districts or facilities; for example, failure to achieve vaccination coverage targets (see the following graph) may be due to lack of vaccine, high proportion of parental refusals, high proportion of contraindications, or simply poor performance of area providers. Once the reason(s) is known, the district/region can tailor measures to correct the problem.




### ▲ Drop-out rates

Drop-out rate refers to the proportion of children who receive the first dose of a 3-dose vaccination series but do not get the final (third) dose. High drop-out rates will impede reaching vaccination coverage targets. Specific reasons for dropping out of the immunization schedule (contraindications? refusals? no vaccine?) need to be investigated using the information from other tables. For example, a combination of a low drop-out rate and a low coverage rate may indicate that a hard-to-reach population group is not getting even the first dose of the series (as seen in District 7 in the following graph). A negative drop-out rate is associated with poor data quality, often from the data having been tampered with at the peripheral level to make an impression of a better-than-actual performance.




▲ **Proportion of children immunized after established “deadlines”**

Vaccinating children much later than envisioned in the immunization calendar is often inappropriate, because such children are left unprotected and susceptible to potentially life-threatening diseases. The following graph indicates that many districts are not putting adequate efforts in reaching children before their first birthday.




By looking at other data, one can also show the effects of untimely vaccinations. Note in the following figure how delayed pertussis immunization for more than 25 percent of children has resulted in a very high pertussis morbidity rate in this region.



▲ **Proportion of children immunized with DT as opposed to DPT**

Because GEOVAC facilitates data entry and analysis, managers will have time to explore many technical issues that they may not have looked at previously. For example, inappropriate practices like the one depicted in the following graph (9 percent of children immunized with DT as opposed to DPT) are often limited to only a few regions. The issue can be resolved through re-training of pediatricians in those areas.



### 4.3 Tables and Graphs on Contraindications and Refusals


Medical contraindications and parental refusals are the main barriers to timely immunization of children.

GEOVAC allows the user to analyze these barriers by type (short-term, long-term, permanent), by region/district/town, by month, and by structure (e.g., DPT 1, 2 or 3). DPT vaccine has been chosen as a marker reflecting the situation with immunizations in general.

The following graphs and tables illustrate selected functions of the application related to the monitoring of the main immunization barriers.


#### ▲ Percentage of children with long-term, permanent, and short-term contraindications to DPT 1-3 by month

The issue of excessively administered contraindications (according to the World Health Organization, the rate of long-term and permanent contraindications should be less than 2 percent of children under 1 year of age) could be addressed through specific training of physicians and changes in regulations such as limiting the authority of a physician to delay immunization for 1 month only. Longer-term contraindications can be authorized only by the decisions of a district physician board. The graph below demonstrates that efforts to reduce contraindications using these strategies were successful in bringing down contraindications.



▲ **Percentage of children with long-term, permanent, and short-term contraindications to DPT 1-3 by district and month**

Further analysis can be very enlightening, and GEOVAC can help examine whether the problem is widespread or confined to individual districts. The following graph looks at the issue of contraindications to DPT 1-3, this time, by district, for selected month(s). As the graph shows, the problem is, in fact, confined to just a few districts, which makes it easier to address.



▲ **Percentage of children with refusals to DPT 1-3 by month and district**

With the help of the GEOVAC tool, it is not very difficult to identify areas (see highlighted rows) where parental education needs to be strengthened.

Rayon/Town	REFUSALS TO DPT 1-3											
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
District 1	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%
District 2	0%	0%	0%	7%	4%	0%	0%	0%	0%	0%	0%	0%
District 3	19%	17%	14%	0%	10%	11%	9%	3%	5%	5%	5%	5%
District 4	12%	7%	6%	3%	16%	7%	9%	4%	5%	11%	10%	10%
District 5	20%	24%	13%	7%	5%	4%	10%	6%	6%	2%	4%	3%
District 6	11%	13%	2%	12%	15%	12%	11%	11%	10%	12%	12%	8%
District 7	8%	12%	12%	15%	6%	4%	5%	4%	4%	5%	8%	6%
District 8	1%	3%	2%	7%	5%	7%	3%	4%	4%	1%	3%	0%
District 9	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%
District 10	0%	0%	0%	9%	7%	6%	8%	4%	9%	0%	4%	2%
District 11	9%	0%	0%	9%	9%	6%	9%	0%	6%	21%	4%	4%
District 12	0%	0%	3%	0%	8%	0%	3%	6%	3%	7%	6%	7%
<b>TOTAL</b>	<b>12.9%</b>	<b>14.7%</b>	<b>7.6%</b>	<b>13.2%</b>	<b>11.6%</b>	<b>13.0%</b>	<b>10.4%</b>	<b>6.2%</b>	<b>8.3%</b>	<b>7.8%</b>	<b>9.0%</b>	<b>6.7%</b>

## 4.4 Tables and Graphs on Vaccine Flow and Use

For each of the vaccines used in Georgia, the GEOVAC worksheets allow the following to be done:

- ▲ Monitor vaccine flow by region and district every month
- ▲ Determine/project an annual need in vaccines at each level and monitor the proportion of the need already received
- ▲ Monitor vaccine balances at regional and district stores and in health facilities on a monthly basis
- ▲ Determine and monitor vaccine usage/wastage patterns by region/district and month

The following graphs and tables illustrate selected functions of the application related to the monitoring of vaccine flow and use

- ▲ **Projections of annual vaccine needs by rayon and by antigen**
- ▲ **Vaccine flow by antigen and by month**

WORKSHEET ON VACCINE NEED AND FLOW				Hepatitis B & Measles - flow	Region ZZ												2003			
HEP B																				
Rayons/towns	Rayon wastage factor (projected)	Annual need (doses)	Balance on 31.12	Shortfall (doses)	Received from RPHC												Total received (doses)	Received + balance (doses)	% of the annual need	Used doses reported
					Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec				
District 1	1.30	2,706	132	2,574	240	174	300	0	0	60	460	0	0	0	0	0	1,234	1,366	50%	1,008
District 2	1.30	3,221	0	3,221	190	0	480	0	1,080	0	0	0	0	0	0	0	1,750	1,750	54%	1,186
District 3	1.30	1,183	54	1,129	84	0	300	0	240	0	420	0	0	0	0	0	1,044	1,098	93%	744
District 4	1.30	3,513	0	3,513	192	1,236	0	600	420	0	0	0	0	0	0	0	2,448	2,448	70%	2,118
District 5	1.30	2,605	24	2,581	540	0	120	720	0	210	210	0	0	0	0	0	1,800	1,824	70%	1,510
District 6	1.30	2,631	372	2,259	0	1,800	0	0	0	0	0	0	0	0	0	0	1,800	2,172	83%	1,488
District 7	1.30	2,129	0	2,129	60	360	504	0	0	120	420	0	0	0	0	0	1,464	1,464	69%	1,128
District 8	1.30	1,399	48	1,351	72	210	96	180	252	150	60	0	0	0	0	0	1,020	1,068	76%	912
<b>TOTAL</b>	1.30	19,386	630	18,756	1,378	3,780	1,800	1,500	1,992	540	1,570	0	0	0	0	0	12,560	13,190	68%	10,094
MEASLES																				
Rayons/towns	Rayon wastage factor (projected)	Annual need (doses)	Balance on 31.12	Shortfall (doses)	Received from RPHC												Total received (doses)	Received + balance (doses)	% of the annual need	Used doses reported
					Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec				
District 1	1.60	2,420	440	1,980	0	0	1,200	0	0	0	1,870	0	0	0	0	0	3,070	3,510	145%	980
District 2	1.60	3,026	190	2,836	200	0	800	0	1,100	0	0	0	0	0	0	0	2,100	2,290	75%	1,440
District 3	1.60	1,260	80	1,180	80	0	600	0	0	0	1,110	0	0	0	0	0	1,790	1,870	148%	600
District 4	1.60	3,770	0	3,770	0	610	300	0	0	160	0	0	0	0	0	0	1,070	4,870	28%	1,380
District 5	1.60	2,734	130	2,604	300	0	1,300	0	0	0	1,000	0	0	0	0	0	2,600	2,730	100%	1,350
District 6	1.60	2,760	610	2,150	0	860	0	0	0	0	1,000	0	0	0	0	0	1,860	2,470	89%	1,040
District 7	1.60	2,194	110	2,084	0	240	1,000	0	0	0	1,200	0	0	0	0	0	2,400	2,550	118%	850
District 8	1.60	1,564	500	1,064	100	100	800	0	0	0	1,800	0	0	0	0	0	2,000	2,500	160%	630
<b>TOTAL</b>	1.60	19,688	2,060	17,628	680	1,810	6,000	0	1,100	160	7,180	0	0	0	0	0	16,930	18,990	96%	8,468


Annual need projections can take into account individual wastage rates in districts

Incorrectly reported measles vaccine receipts (1380 doses used, but only 1070 received)

Excessive supply increases the risk of vaccine damage due to improper storage conditions and may lead to stock-outs elsewhere

▲ **Vaccine wastage by region, district, antigen, quarter**

Vaccine wastage information can be displayed in many different ways, all of which provide the manager with critical information to understand the extent of the problem, the location of the problem, and other explanatory factors.



Monitoring wastage by quarter at every level allows immunization managers to see if the applied wastage reduction strategies work or not. Automatically highlighted vaccine use rates indicate excessive levels of vaccine usage. Vaccine wastage monitoring may also help determine areas where additional efforts are needed.

WORKSHEET ON THE USE OF VACCINE		Hepatitis B & Measles - usage		in Region XX		2003										
<b>HEP B</b>																
Rayons/towns	January	February	March	April	May	June	July	August	September	October	November	December	Number of doses used per 1 vaccination			
	used (dose) Immunizations made	I quarter	II quarter	III quarter	IV quarter											
District 1	576 359	462 230	420 248	438 331	396 301	402 340	462 400	270 237	558 489	750 693	676 612	703 650	1.76	1.27	1.15	1.08
District 2	30 22	90 66	64 60	84 78	102 79	78 50	96 64	78 46	115 96	108 80	102 73	101 66	1.49	1.29	1.41	1.42
District 3	222 92	186 104	192 154	168 130	288 183	186 97	258 115	168 149	234 143	300 252	210 168	210 180	1.71	1.57	1.62	1.20
District 4	78 74	168 136	222 146	210 140	162 154	198 177	210 183	192 166	394 255	186 146	138 111	174 148	1.32	1.21	1.21	1.23
District 5	42 31	84 64	84 55	90 55	78 48	108 81	78 54	66 51	90 68	63 49	72 65	85 61	1.40	1.50	1.35	1.28
District 6	60 47	30 26	78 57	48 43	90 40	66 47	72 54	48 38	120 51	102 69	72 63	66 50	1.29	1.47	1.68	1.32
District 7	114 105	240 186	210 201	186 166	300 216	216 208	216 193	216 187	300 279	408 327	312 283	269 259	1.15	1.19	1.11	1.14
District 8	78 27	186 117	121 69	96 87	132 90	162 77	108 65	60 30	188 138	183 88	156 101	173 73	1.81	1.48	1.53	1.95
District 9	382 64	96 54	126 88	126 83	168 125	180 117	144 79	90 42	130 106	108 91	140 117	132 108	2.96	1.46	1.60	1.20
District 10	36 22	132 116	240 168	132 124	120 114	138 109	198 124	150 122	185 164	175 165	174 149	205 171	1.33	1.12	1.30	1.14
District 11	60 49	96 58	96 81	132 72	126 92	118 47	164 64	66 52	174 66	114 61	60 55	156 92	1.34	1.77	2.22	1.67
District 12	12 11	96 57	72 55	90 73	108 74	72 70	108 69	48 31	146 100	100 53	96 52	38 41	1.46	1.24	1.74	1.74
<b>TOTAL</b>	1680 903	1866 1202	1945 1278	1800 1380	2070 1535	1924 1420	2114 1444	1452 1140	2534 1955	2597 2073	2208 1840	2338 1899	1.58	1.34	1.34	1.23
<b>MEASLES</b>																
Rayons/towns	January	February	March	April	May	June	July	August	September	October	November	December	Number of doses used per 1 vaccination			
	used (dose) Immunizations made	I quarter	II quarter	III quarter	IV quarter											
District 1	460 280	610 304	630 488	590 387	520 304	650 381	540 400	340 249	990 609	460 327	390 318	292 143	1.60	1.66	1.53	1.45
District 2	50 12	50 22	80 31	60 22	120 55	120 52	100 40	70 39	150 56	40 20	120 78	74 58	2.77	2.27	2.54	1.50
District 3	290 80	200 62	150 102	170 72	250 79	130 55	220 83	200 84	340 211	240 179	100 69	132 108	2.71	2.66	2.25	1.33
District 4	90 59	90 66	120 98	130 91	100 67	150 77	130 78	220 180	460 351	80 65	110 99	96 72	1.35	1.69	1.33	1.27
District 5	100 33	110 38	260 69	140 24	80 39	140 57	140 70	80 45	120 46	80 37	20 17	54 42	3.62	3.00	2.11	1.60
District 6	100 33	60 58	80 72	50 37	60 24	50 27	30 26	40 27	110 81	70 48	20 12	54 34	1.49	1.82	1.34	1.53
District 7	260 108	260 230	180 137	160 121	180 94	200 116	270 164	400 247	300 223	200 99	190 90	144 129	1.41	1.63	1.53	1.68
District 8	70 30	120 33	80 19	50 36	110 95	250 126	170 55	50 31	160 113	150 74	20 7	122 75	3.29	1.60	1.91	1.87
District 9	230 70	130 79	170 52	150 71	190 74	160 60	122 90	150 61	130 69	140 58	160 57	72 68	2.64	2.44	1.76	2.08
District 10	120 74	70 16	120 60	90 38	140 96	190 151	440 318	170 132	140 102	120 76	110 65	84 46	2.88	1.47	1.36	1.69
District 11	60 10	130 22	80 22	80 25	110 39	60 15	100 19	120 44	150 83	80 32	60 27	96 57	5.00	3.16	2.53	2.03
District 12	50 28	80 36	70 25	120 34	90 49	210 148	160 108	70 31	120 31	60 53	40 14	50 48	2.30	1.82	2.06	1.30
<b>TOTAL</b>	1820 785	1910 1063	2020 1095	1780 929	1950 1018	2310 1265	2422 1438	1910 1130	3070 1875	1720 1085	1340 843	1270 876	1.97	1.88	1.66	1.56

Wastage reduction strategies seem to be working in this region: note how wastage factor decreases every quarter

Optimization of procurement through a mix of different size vial products and adoption of wastage reduction policies (such as multi-dose policy) nationwide may free up funds for the procurement of other vaccines, like rubella, which currently appear to be unaffordable.

VACCINE USAGE summary in Region XX															2003			Vaccine Usage Summary												
Rayons (Towns)	BCG			Polio			DPT			Hepatitis B			DT			Measles			Mumps			Rubella			MMR			Td		
	Doses Used	Immunizations Made	USAGE factor	Doses Used	Immunizations Made	USAGE factor	Doses Used	Immunizations Made	USAGE factor	Doses Used	Immunizations Made	USAGE factor	Doses Used	Immunizations Made	USAGE factor	Doses Used	Immunizations Made	USAGE factor	Doses Used	Immunizations Made	USAGE factor	Doses Used	Immunizations Made	USAGE factor	Doses Used	Immunizations Made	USAGE factor	Doses Used	Immunizations Made	USAGE factor
District 1	7,400	2,301	3.22	12,270	8,044	1.53	8,481	6,803	1.28	6,113	4,898	1.25	1,150	990	1.16	6,362	4,059	1.57	2,774	2,540	1.09	0	0	###	0	0	###	2,480	1,846	1.34
District 2	740	134	5.52	2,440	1,140	2.14	1,700	903	1.88	1,068	766	1.39	370	219	1.69	1,034	478	2.16	456	385	1.18	0	0	###	0	0	###	510	431	1.18
District 3	1,170	215	5.44	5,300	2,410	2.20	3,630	2,107	1.72	2,822	1,767	1.48	290	167	1.74	2,362	1,113	2.12	1,216	721	1.69	0	0	###	0	0	###	851	638	1.33
District 4	850	415	2.05	3,830	2,669	1.43	3,180	2,540	1.25	2,232	1,804	1.24	80	59	1.36	1,776	1,281	1.39	968	815	1.19	0	0	###	0	0	###	620	496	1.25
District 5	700	153	4.58	2,150	1,091	1.97	1,660	1,055	1.57	944	682	1.38	110	23	4.78	1,324	507	2.61	360	287	1.26	0	0	###	0	0	###	350	279	1.25
District 6	440	60	7.33	1,510	1,124	1.34	1,350	974	1.39	852	594	1.40	200	137	1.46	724	477	1.52	445	350	1.27	0	0	###	0	0	###	465	371	1.25
District 7	1,260	580	2.17	4,950	3,742	1.32	4,060	3,238	1.25	2,987	2,610	1.14	187	160	1.17	2,744	1,778	1.54	772	720	1.07	0	0	###	0	0	###	1,110	879	1.26
District 8	900	244	3.69	3,710	1,504	2.47	2,340	1,304	1.79	1,643	971	1.69	360	148	2.43	1,352	694	1.95	678	505	1.34	0	0	###	0	0	###	640	440	1.45
District 9	1,190	290	4.10	3,800	2,085	1.82	3,240	1,957	1.66	1,822	1,072	1.70	220	134	1.64	1,804	814	2.22	774	579	1.34	0	0	###	0	0	###	558	399	1.39
District 10	840	316	2.66	3,450	2,166	1.59	2,664	1,799	1.48	1,885	1,548	1.22	530	322	1.65	1,794	1,172	1.53	808	699	1.16	0	0	###	0	0	###	800	595	1.37
District 11	500	42	###	3,120	1,239	2.52	2,130	967	2.20	1,362	780	1.75	380	170	2.24	1,126	395	2.85	658	412	1.60	0	0	###	0	0	###	620	349	1.40
District 12	620	108	5.74	2,050	1,097	1.87	1,680	944	1.78	1,006	686	1.47	250	125	2.00	1,120	603	1.86	500	393	1.27	0	0	###	0	0	###	550	402	1.37
<b>TOTAL</b>	16,610	4,539	3.42	46,480	28,911	1.72	36,115	24,889	1.48	24,538	18,178	1.35	4,127	2,654	1.56	23,622	13,971	1.76	10,409	8,406	1.24	0	0	#DIV/0!	0	0	#DIV/0!	9,452	7,115	1.33

▲ Vaccine balances at health settings and CPH by antigen, month and district

Rational vaccine stock management is a key to the uninterrupted functioning of the immunization program.

The GEOVAC Worksheet on the Balance of Vaccines makes this task easier by helping health workers determine a “safety minimum” of vaccine stock at their level in order to re-order vaccines in a timely manner when available supplies drop below the recommended level. The table below demonstrates that few districts have the necessary safety minimum in stock and some have critical stock-outs of major vaccines.

WORKSHEET ON THE BALANCE OF VACCINES in CPH and health settings at the end of																								
December		Region XX 2003																						
Rayons/towns	BCG				POLIO				DPT				DT				Td				Hepatitis B			
	in RPHC	in health settings	RPHC + health settings	Safety minimum	in RPHC	in health settings	RPHC + health settings	Safety minimum	in RPHC	in health settings	RPHC + health settings	Safety minimum	in RPHC	in health settings	RPHC + health settings	Safety minimum	in RPHC	in health settings	RPHC + health settings	Safety minimum				
District 1	780	200	980	3,242	1020	0	1,020	4,288	660	490	1,150	3,066	920	210	1,130	1,225	320	400	720	1,073	954	584	1,538	2,604
District 2	100	40	140	267	260	0	260	325	210	10	220	258	10	0	10	87	190	0	190	160	78	46	124	275
District 3	40	20	60	653	280	0	280	820	260	80	340	675	60	40	100	178	70	20	90	336	186	12	198	666
District 4	120	20	140	844	110	0	110	1,152	160	10	170	867	150	0	150	471	30	10	40	623	102	42	144	688
District 5	40	0	40	347	120	0	120	482	120	10	130	365	0	0	0	145	100	0	100	172	30	9	39	262
District 6	80	0	80	301	140	0	140	434	110	90	200	300	30	30	50	426	60	20	80	679	186	42	228	275
District 7	40	60	100	1,034	60	0	60	1,158	50	80	130	930	0	43	43	306	30	0	30	366	0	49	49	825
District 8	0	100	100	488	190	0	190	635	180	60	240	470	240	50	290	382	70	20	90	544	288	30	318	423
District 9	140	0	140	649	300	0	300	875	340	190	530	648	20	10	30	252	170	60	230	330	222	112	334	503
District 10	0	0	0	575	0	0	0	729	70	156	226	595	0	40	40	178	80	60	140	226	90	90	180	415
District 11	0	200	200	269	490	0	490	401	160	90	250	329	80	20	100	111	140	0	140	127	114	42	156	275
District 12	80	0	80	338	120	0	120	356	170	0	170	275	0	0	0	105	50	0	50	132	49	0	49	212
<b>TOTAL</b>	1,420	640	2,060	9,106	3,090	0	3,090	11,656	2,490	1,266	3,796	8,779	1,500	443	1,943	3,864	1,310	590	1,900	4,767	2,299	1,058	3,357	7,424

Critical vaccine stock-outs of major vaccines



## 5. In Conclusion

Countries that plan to strengthen their immunization information systems as well as donor organizations that are interested in supporting these efforts should consider investing a small portion of their funds in the development of a simple and unpretentious supplementary tool such as the GEOVAC application, which can easily be maintained and modified in-country, without external technical assistance.

Such a tool systematizes the process of using information technology for immunization data processing at the provincial and peripheral levels in countries where health systems are underfunded, but where, nevertheless, technology is becoming widely available. It makes data processing and analysis much more efficient, and allows users to quickly find the underlying roots of the problems and to perform the types of analyses that they may not have done before due to either mathematical complexity or limited amount of time available for data processing.

Because it transforms data into information rapidly and in a format that assists interpretation, a software application like GEOVAC is also a very powerful tool to facilitate data utilization for management at all levels of the health system. Some examples of the types of managerial decisions made with the help of GEOVAC that were observed in Georgia included improved vaccine supply management resulting in fewer stock-outs at the peripheral level, establishment of physician commissions to deal with excessive administration of contraindications, timely follow-up with poorly performing facilities, and adoption of new vaccine wastage reduction strategies, such as the multi-dose policy, stakeholder discussions of the need to optimize the national vaccine procurement strategy.

Although GEOVAC was developed specifically for the Immunization MIS system in Georgia, similar software could easily be created for other countries that wish to improve their MIS.



# Annex: Sample District Level Immunization

REPORT on CONDUCTED PREVENTIVE VACCINATIONS									
Distict 1		November		2003					
Immunizations Given				Use of Vaccine in Doses					
Vaccine	Age at vaccination	Number of vaccinated	Total Immunizations Given	Balance at the beginning of the period (dose)	Received (dose)	ISSUED (dose)	Balance at the Payon DPH the end of the period (dose)	BALANCE at health care settings at the end of the period (dose)	TOTAL AMOUNT OF VACCINE USED (dose)
1	2	3	4	5	6	7	8=5+6-7	9 from column 7 (1,8)	10 from column 8 (1,8)
<b>BCC-v</b>	0-5 days		Total						
	More than 6 days		<b>0</b>				0		
<b>BCC -2</b>	5 years +								
<b>DPT-1</b>	2months -11mo 29d	13	Total						
	More than 1 year	4							
<b>Diphtheria-Tetanus-Pertusis -1</b>	3months -11mo 29d	23							
<b>Diphtheria-Tetanus-Pertusis -2</b>	More than 1 year	3	<b>86</b>	140	200	150	190	30	150
	DPT-3	4months -11mo 29d							
<b>Diphtheria-Tetanus-Pertusis -3</b>	More than 1 year	6							
	DPT-4	18 - 24 months	21						
<b>Diphtheria-Tetanus-Pertusis -4</b>	More than 24 months	4							
<b>DT-1</b>	under 1 year		Total						
	More than 1 year								
<b>Diphtheria-Tetanus - 1</b>	under 1 year		<b>0</b>				0		
	More than 1 year								
<b>DT-2</b>	under 1 year								
	More than 1 year								
<b>Diphtheria-Tetanus - 2</b>	under 1 year								
	More than 1 year								
<b>DT-3</b>	under 1 year								
	More than 1 year								
<b>Diphtheria-Tetanus - 3</b>	18 months +								
	DT-4	18 months +							
<b>DT</b>	5 years- 5 y11mo29d								
	More than 6 years								
<b>Diphtheria-Tetanus</b>									
<b>OPV-1</b>	2months -11mo 29d	13	Total						
	More than 1 year	4							
<b>Poliomyelitis -1</b>	3months -11mo 29d	23							
<b>OPV-2</b>	More than 1 year	3	<b>137</b>	280	200	150	330	30	190
	OPV-3	4months -11mo 29d							
<b>Poliomyelitis -3</b>	More than 1 year	6							
	OPV-4	18 - 24 months	21						
<b>Poliomyelitis -4</b>	More than 24 months	4							
<b>OPV-5</b>	5 years- 5 y11mo29d	50							
	More than 6 years	1							
<b>Other OPVs</b>									
<b>VHB-1</b>	0-24 hours	7	Total						
	25 hours -11mo 29d	3							
	More than 1 year	4							
<b>Viral Hepatitis B-1</b>	2months -11mo 29d	24	<b>73</b>	60	120	102	78	36	102
	More than 1 year	2							
<b>Viral Hepatitis B-2</b>	3months -11mo 29d	23							
	More than 1 year	10							
<b>Viral Hepatitis B-3</b>	More than 1 year								
<b>Other Hepatitis B-1</b>									
<b>Other Hepatitis B-2</b>									
<b>Other Hepatitis B-3</b>									
<b>Measles 1</b>	12 -24 month	24	Total						
	More than 24 months								
<b>Measles -2</b>	5 years- 5 y11mo29d	54	<b>78</b>	120		100	20	20	120
	More than 6 years								
<b>Other Measles</b>									
<b>Mumps</b>	12 -24 month	20	Total						
	More than 24 months	24	<b>44</b>	66		38	28	12	48
<b>Other Mumps</b>									
<b>Rubella</b>	12 -24 month		Total				0		
	More than 24 months		<b>0</b>						
<b>MMR</b>	12 -24 months		Total				0		
	More than 24 months								
	5 years - 5y11mo29d		<b>0</b>						
	More than 6 years								
<b>MR</b>	12 -24 months		Total				0		
	More than 24 months								
	5 years - 5y11mo29d		<b>0</b>						
	More than 6 years								
<b>Td Tetanus - Diphtheria</b>	14 years	104	Total	150	100	60	190	10	120
<b>Td Other</b>			<b>104</b>						
<b>Syringe Disposal Containers</b>				16	12	3	25	11	3
<b>TIMELINESS</b>	No. of children born in June 2003 (<5mo prior to the report month)=>								15
	Of these - no. of children who finished primary immunization at 4mo29d=>								7
<b>REFUSALS</b>		<b>CONTRAINDICATIONS TO DTP</b>							
				Short-term	Long-term	Permanent			
DTP-1 (under 1y)	0	DTP-1 (under 1y)			2				
DTP-2 (under 1y)	0	DTP-2 (under 1y)		1	1				
DTP-3 (under 1y)	0	DTP-3 (under 1y)		2					
<b>TOTAL refusals</b>	<b>0</b>	<b>TOTAL contraindications (short+long+perm)</b>					<b>6</b>		